Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Abbott launches paediatric offering for Humira

Abbott launches paediatric offering for Humira

16th June 2011

Abbott has announced the launch of a paediatric vial offering for its juvenile idiopathic arthritis (JIA) treatment Humira.

The new version of the drug can be used among patients as young as four years old and has been released in the UK following approval of the new indication from European regulators in March.

It means that the treatment is now available to all active polyarticular juvenile idiopathic arthritis patients aged between four and 17 years old who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.

Abbott states that the efficacy of Humira among younger patients has been supported by clinical data, which shows the benefits of the drug in alleviating the signs and symptoms of JIA.

Dr Jackie Harris, director of immunology at Abbott, said: "The Humira license extension demonstrates Abbott's continued commitment to rheumatology as this means it is now licensed for a full range of indications."

This comes after the drug demonstrated its efficacy when prescribed to rheumatoid arthritis sufferers at an early stage in clinical data published last month.ADNFCR-8000103-ID-800581016-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.